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Summary
BACKGROUND: In Switzerland, intravenous drug use
(IDU) accounts for 80% of newly acquired hepatitis C virus
(HCV) infections. Early HCV treatment has the potential to
interrupt the transmission chain and reduce morbidity/mor-
tality due to decompensated liver cirrhosis and hepatocel-
lular carcinoma. Nevertheless, patients in drug substitution
programs are often insufficiently screened and treated.
Alphabetic list of abbreviations
DOT Directly observed therapy
H22 Methadone substitution program of the Outpatient Clinic of the
Department of Infectious Diseases of the Cantonal Hospital St.
Gallen
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
HIV Human immunodeficiency virus
i.v. Intravenous
IDU Intravenous drug use
KODA Heroin substitution program Bern
MSH1 Heroin substitution program of the addiction aid trust St.
Gallen
MSH2 Methadone substitution program of the addiction aid trust
St. Gallen
SCCS Swiss Hepatitis C Cohort Study
SHCS Swiss HIV Cohort Study
SVR Sustained virological response (HCV RNA negative 6 months
after the end of treatment)
OBJECTIVE/METHODS: With the aim to improve HCV
management in IDUs, we conducted a cross sectional chart
review in three opioid substitution programs in St. Gallen
(125 methadone and 71 heroin recipients). Results were
compared with another heroin substitution program in Bern
(202 patients) and SCCS/SHCS data.
RESULTS: Among the methadone/heroin recipients in St.
Gallen, diagnostic workup of HCV was better than expec-
ted: HCV/HIV-status was unknown in only 1% (2/196),
HCV RNA was not performed in 9% (13/146) of anti-
HCV-positives and the genotype missing in 15% (12/78) of
HCV RNA-positives. In those without spontaneous clear-
ance (two thirds), HCV treatment uptake was 23% (21/
91) (HIV-: 29% (20/68), HIV+: 4% (1/23)), which was
lower than in methadone/heroin recipients and particularly
non-IDUs within the SCCS/SHCS, but higher than in the,
mainly psychiatrically focussed, heroin substitution pro-
gram in Bern (8%). Sustained virological response (SVR)
rates were comparable in all settings (overall: 50%, gen-
otype 1: 35–40%, genotype 3: two thirds). In St. Gallen,
the median delay from the estimated date of infection (IDU
start) to first diagnosis was 10 years and to treatment was
another 7.5 years.
CONCLUSIONS: Future efforts need to focus on earlier
HCV diagnosis and improvement of treatment uptake
among patients in drug substitution programs, particularly
if patients are HIV-co-infected. New potent drugs might fa-
cilitate the decision to initiate treatment.
Key words: methadone; heroin; drug substitution
program; spontaneous clearance; HCV treatment uptake;
HCV treatment success; HIV-HCV-co-infection; genotype
distribution; potential treatment barriers; delay of
diagnosis and treatment
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Introduction
In Switzerland, approximately 80% of newly acquired hep-
atitis C virus (HCV) infections are due to sharing injection
equipment among intravenous drug users (IDUs) [1]. In
Western Europe, HCV seroprevalence ranges from 33% to
98% in this population [2]. Due to the slow progression of
the disease, the peak of hepatitis C induced liver failure is
not expected until 2015, despite a currently decreasing in-
cidence [3].
Thus, successful HCV treatment not only results in an indi-
vidual benefit by preventing progression to decompensated
liver cirrhosis and hepatocellular carcinoma (HCC), but
may also help to contain the epidemic by eliminating a po-
tential source of infection. Although treatment adherence,
side effects and treatment response do not differ between
IDUs and non-IDUs [4–6], several studies have shown that
HCV treatment uptake is substantially lower in patients in
opioid substitution programs compared to non-IDUs (8.7%
versus 44% according to Swiss Hepatitis C Cohort data
from 2006/2007) [2, 7, 8].
A total of 8% of the patients in opioid substitution pro-
grams are HIV-HCV-co-infected and thus prone to exper-
ience faster progression to liver cirrhosis [9, 10]. Mean-
while, in HIV-patients, liver failure has advanced to be-
come the second most frequent cause of death after AIDS
[11–14].
At the end of 2005, 16’200 patients (56% of all Swiss
opioid dependants) were cared for in drug substitution pro-
grams (80% methadone, 8% heroin, 3% buprenorphine)
[2]. Long term abstinence is achieved in only 25–33% of
all opioid dependants. On the other hand, after 2.5 years
50% are still in the heroin program and 25% remain there
for >10 years [3]. Long term care with a once to twice daily
appearance provides an ideal setting for directly observed
therapy (DOT) of hepatitis C [15, 16] (and other diseases
such as HIV). The re-infection rate after successful treat-
ment of chronic hepatitis C is 7% for active IDUs [1].
For several years, the three main drug substitution pro-
grams in St. Gallen (H22, MSH1 and MSH2) have had a
somatic physician on site, whereas the heroin substitution
program in Bern (KODA) has a more psychiatric focus.
Differences in the quality of HCV management could ac-
centuate the need for improving somatic care in a mainly
psychiatric setting.
The Swiss Hepatitis C Cohort Study (SCCS) enrols both
HCV-mono- and HIV-HCV-co-infected patients, whereas
the Swiss HIV Cohort Study (SHCS) is restricted to HIV-
HCV-co-infected patients because HIV-positivity is an in-
clusion criterion. The SCCS does not include HCV-neg-
ative people and the SHCS does not enrol HIV-negative
people at risk of the respective infection. SCCS or SHCS
participation requires regular cohort visits once or twice a
year and implies a certain standard of care. Only patients
expected to be compliant enough will be included. The
drop-out rate is as high as 31% in the SCCS, with parti-
cipants lost to follow-up being more likely to be younger
and to have injection drug use as a reported risk factor [7].
In the light of existing recommendations from the Swiss
Society of Addiction Medicine [2], the purpose of this
study was to evaluate the current state of HCV manage-
ment in the three largest opioid substitution programs in
St. Gallen (125 methadone and 71 heroin recipients) and
to identify potential targets for future optimisation. In a
second step, we compared demographic and treatment data
with data from a heroin substitution program with a psy-
chiatric focus in Bern (202 patients), as well as with SCCS
and SHCS data as a benchmark. We hypothesised that
HCV treatment uptake-rates are lower in patients enrolled
in the drug substitution programs (i.e. former or still active
IDUs), lower than in SCCS/SHCS-participants in general
and non-IDUs in particular. Furthermore, HCV treatment
uptake-rates were compared between heroin/methadone re-
cipients and non-IDUs within the SCCS and SHCS, re-
spectively.
Patients and Methods
Three opioid substitution programs in St. Gallen
In December 2009, a cross sectional study was performed
in a total of 196 patients evaluating the HCV-management
in the three largest opioid substitution programs in St. Gal-
len. All patients enrolled in these institutions at the time
of the study were included (MSH1: 71 heroin recipients;
MSH2: 90 methadone recipients, H22 (Outpatient Clinic of
the Department of Infectious Diseases of the Cantonal Hos-
pital St. Gallen): 35 methadone recipients). Data were col-
lected by review of paper and electronic medical records.
Heroin substitution program KODA in Bern
Since 1995, KODA Bern has provided heroin substitution
(twice daily i.v., switch to or combination with methadone
possible), basic somatic, psychiatric and nursing care for
≥18-year-old patients with a history of IDU of 2 years or
more and at least 2 failed abstinence oriented treatments.
In 2008, a cross-sectional survey was performed in all
202 IDUs treated in KODA at that time (median age: 39
years (range: 21–71), 28% female), to evaluate their somat-
ic health status and the need for improving on-site somatic
care.
SCCS (Swiss Hepatitis C Cohort Study)
The SCCS is a prospective multicentre study carried out
at 8 major Swiss hospitals and their local affiliated centres
which has recruited HCV-positive patients since September
2000 [7]. In April 2010, it had 3’602 participants (median
age: 48 years, 37% female, 10% HIV-co-infected, 24% in
drug substitution programs, 43% without IDU as a risk
factor).
SHCS (Swiss HIV Cohort Study)
The SHCS is a prospective multicentre study carried out
at 7 major Swiss hospitals and their local affiliated centres
which has enrolled HIV-positive patients since 1988
(www.shcs.ch) [17]. In April 2010, 16’285 participants
were included (median age: 48 years, 29% female, 29%
HCV-co-infected, 9% in drug substitution programs, 71%
without IDU as a risk factor).
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Data collection and analysis
In the cross sectional, retrospective, chart review conduc-
ted in the three largest opioid substitution programs in St.
Gallen, we focussed on the following issues: screening for
HCV and HIV, immunisation against hepatitis A and B,
proportion of SCCS and SHCS participation, rate of HCV
treatment uptake in mono- and HIV-co-infected patients,
delay of HCV diagnosis and treatment, HCV treatment re-
sponse rates, potential barriers to treatment and, with re-
gard to new drugs which will be available soon, genotype
distribution of those still in need for treatment.
In a second step, we compared demographic and treatment
data with data from a similar cross-sectional survey in
a heroin substitution program with a psychiatric focus
(KODA Bern), as well as with SCCS and SHCS data as
a benchmark. Updated data sets from the SCCS and the
SHCS were provided in the framework of a specific cohort
project involving both cohorts (SHCS #639, SCCS: no pro-
ject number available). We hypothesised that HCV treat-
ment uptake-rates would be lower in patients enrolled in
the drug substitution programs (i.e. former or still active
IDUs), lower than in SCCS/SHCS-participants in general
and non-IDUs in particular. Furthermore, HCV treatment
uptake-rates were compared between heroin/methadone re-
cipients and non-IDUs within the SCCS and SHCS, re-
spectively.
Definitions
First diagnosis of HCV was defined as the first documented
positive HCV antibody test or the time point since the pa-
tient first knew (that) he was HCV-positive – whichever
came first.
Spontaneous clearance rate was calculated as the ratio
between patients HCV RNA-negative without treatment
and all anti-HCV-positive patients with available HCV
RNA.
Statistical methods
Statistical analyses were performed using Open Source
Epidemiologic Statistics for Public Health, Version 2.3
(www.OpenEpi.com). Categorical data were assessed in
two-way contingency table analyses by using Chi-square
test, or Fisher’s exact test when the sample size was small.
To demonstrate and quantify factors associated with HCV
treatment uptake and sustained virological response (SVR),
logistic regression derived odds ratios (OR) with 95% con-
fidence intervals (CI) were calculated by means of Taylor
Series. 95% CI not including 1 and p values <0.05 were
considered significant.
Results
Patient characteristics (St. Gallen)
Table 1 shows the characteristics of the patients cared for
in the three drug substitution programs in St. Gallen (exten-
ded version: supplementary table 1).
According to the focus of the programs, MSH2 has no
HIV-patients, while two thirds of the H22-patients are HIV-
HCV-co-infected. The proportion of patients who have not
performed intravenous drug use (never IDU) correlates
with the proportion of patients neither HIV- nor HCV-in-
fected. All HIV-positive patients participate in the SHCS,
whereas only half of the HCV-positive patients are enrolled
in the SCCS.
Fluctuation (i.e. the annual number of admissions and
exits) is highest (about 50% per year), and the proportion
of patients appearing daily is lowest (about three quarter)
in the methadone-substitution program MSH2. In contrast,
the heroin substitution program MSH1 has the lowest fluc-
tuation rate (about 10% per year), all patients attend at least
once daily and 93% even attend several times a day.
HCV- and HIV-screening, HCV- and HIV-prevalence
(St. Gallen and Bern)
In St. Gallen’s opioid substitution programs, HIV- and
HCV-status was unknown in only 1% (2/196) of all pa-
tients. However, in about 50% of negatively screened pa-
tients, the last test was older than one year. In HCV-positive
patients, HCV RNA was not determined in 9% (13/146),
and genotype was missing in 15% (12/78) of HCV RNA-
positive patients.
Prevalence rates were 75% for HCV (59% of them HCV
RNA-positive), 19% for HIV and 18% for HIV-HCV-co-
infection (table 1 and 2).
Comparable numbers were found in KODA Bern, where
HCV- and HIV-screening was missing in only 1% and 5%,
respectively. Out of the patients with available serology,
80% were HCV-positive (65% of them HCV RNA-posit-
ive, genotype available for 8% only) and 13% were HIV-
infected (table 2).
HCV spontaneous clearance, treatment uptake and
success rate (St. Gallen and Bern)
In St. Gallen, the rate of spontaneous clearance was about
one third, both for HCV-mono- and HIV-HCV-co-infected
patients (32/100 and 12/35, respectively). In KODA Bern,
the spontaneous clearance rate was very similar at 32% (48/
150).
Altogether in St. Gallen, the HCV treatment uptake-rate
in those without spontaneous clearance was 23% (21/91)
(29% (20/68) in HCV-mono-infected and 4% (1/23) in
HIV-HCV-co-infected patients).
A total of 47% patients (8/17, 4x still running therapy)
achieved SVR (sustained virological response = HCV
RNA not detectable 6 months after the end of treatment)
(genotype 1: 38% (3/8), genotype 3: 67% (4/6)). The only
HIV-HCV-co-infected patient treated (genotype 1) had un-
detectable HCV RNA at the end of the treatment, but ex-
perienced a relapse (table 2).
In KODA Bern, which had a mainly psychiatric focus until
2008, the HCV treatment uptake rate was somewhat lower
at 8% (8/102) (treatment outcome: SVR in 5/8 patients).
Additional work-up with sonography, liver biopsy,
fibroscan and endoscopy (St. Gallen)
In St. Gallen, HCV RNA-positive patients without spon-
taneous clearance were further evaluated with sonography
in 63% (57/91) (54% splenomegaly), fibroscan in 66% (60/
91) (23% liver stiffness ≥13 kPa) and liver biopsy in 35%
(32/91) (68% fibrosis score ≥2 (Metavir score); median
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time from HCV diagnosis to liver biopsy: 9 years (range:
0–16)).
A gastroscopy was performed in 50% (9/18) of HCV-pos-
itive patients with either sonographically verified liver cir-
Table 1: Characteristics of the three drug substitution programs in St. Gallen.
MSH1 MSH2 H22
Founded 1995 1993 1990
Capacity (patients) Max. 75 Max. 100 35
Yearly fluctuation (patients) about 8 (10%) 50–60 (about 50%) about 5 (14%)
Open (days/week) 7 6 5
Number of patients included in the cross sectional
study
71 90 35
Gender (female) 23% (16/71) 23% (21/90) 31% (11/35)
Median age (years) (range) 42 (26–63) 39 (20–63) 42 (29-61)
Median time in program since last admission
(years) (range)
5.0 (0–14) 2.0 (0–16) 3.7 (0–19)
Frequency of attendance
– daily
– several times a day
100% (71/71)
93% (66/71)
77% (69/90)
1% (1/90)
87% (30/35)
11% (4/35)
Opioid substitution
– heroin
– methadone
– buprenorphine
94% (67/71)
6% (4/71)
0% (0/71)
0% (0/90)
97% (87/90)
3% (3/90)
0% (0/35)
100% (35/35)
0% (0/33)
Never IDU 5% (3/67) 22% (20/90) 0% (0/35)
HIV- and HCV-negative 17% (12/71) 38% (33/87) 0% (0/35)
HCV-infection (anti-HCV+) 82% (58/71) 61% (54/88) 97% (34/35)
HIV-infection 18% (13/71) 0% (0/88) 69% (24/35)
HIV-HCV-co-infection 17% (12/71) 0% (0/87) 66% (23/35)
MSH1 = heroin substitution program of the addiction aid trust St. Gallen, MSH2 = methadone substitution program of the addiction aid trust St. Gallen, H22 = methadone
substitution program of the Outpatient Clinic of the Department of Infectious Diseases of the Cantonal Hospital St. Gallen, max. = maximal, IDU = intravenous drug use,
HIV = Human immunodeficiency virus, HCV = Hepatitis C virus, SCCS = Swiss Hepatitis C Cohort Study, SHCS = Swiss HIV Cohort Study
An extended version of this table can be found in the supplementary material (Supplementary table 1).
Table 2: Patient characteristics, HCV treatment uptake and success rates.
SCCS SHCS St. Gallen Bern
Number of patients 3602 16285 196 202
Median age (years) (range) 48 (19–91) 48 (18–101) 41 (20–63) 39 (21–71)
Gender (female) 37% (1335/3602) 29% (4659/16285) 25% (48/196) 28% (57/202)
Drug substitution program 24% (872/3600) 9% (796/8517) 100% 100%
No IDU 43% (1534/3595) 71% (11326/15960) 12% (23/190) 0%
HCV-infected 100% 29% (3319/11527) 75% (146/194) 80% (161/200)
HCV RNA+, if anti-HCV+ and HCV RNA
available
68% (2425/3575) 67% (1446/2153) 59% (78/133) 65% (97/150)
HIV-infected 10% (285/2974) 100% 19% (37/194) 13% (26/195)
HIV-HCV-co-infected 10% (285/2974) 29% (3319/11527) 18% (35/193) 13% (26/195)
Liver biopsy, if no spontaneous clearance 66% (2234/3374) 40% (696/1752) 35% (32/91) No data
HCV treatment uptake rates SCCS SHCS St. Gallen Bern
– all chronically HCV infected 57% (1915/3374) 28% (497/1752) 23% (21/91) 8% (8/102)
– HIV-HCV-co-infected (HIV+) 33% (82/246) 28% (497/1752) 4% (1/23) 10% (2/21)
– HCV-mono-infected (HIV-) 60% (1517/2519) – 29% (20/68) 7% (6/81)
– all in drug substitution program 38% (282/753) 24% (128/545) 23% (21/91) 8% (8/102)
– all non-IDUs 65% (963/1493) 36% (159/445) – –
Proportion with SVR, if treated SCCS SHCS St. Gallen Bern
– all (with known genotype) 53% (564/1066) 50% (116/230) 47% (8/17) 63% (5/8)
– all with genotype 1 37% (176/474) 36% (32/89) 38% (3/8) 0% (0/1)
– all with genotype 3 66% (264/399) 65% (69/106) 67% (4/6) 71% (5/7)
– all HIV+ (with known genotype) 44% (19/43) 50% (116/230) 0% (0/1) 100% (2/2)
– all HIV- (with known genotype) 54% (464/856) – 50% (8/16) 50% (3/6)
– all in drug substitution program (with
known genotype)
64% (85/133) 46% (26/57) 47% (8/17) 63% (5/8)
– all non-IDUs (with known genotype) 49% (274/557) 54% (41/76) – –
SCCS = Swiss Hepatitis C Cohort Study, SHCS = Swiss HIV Cohort Study, IDU = intravenous drug use, HCV = Hepatitis C virus, HIV = Human immunodeficiency virus,
SVR = sustained virological response (HCV RNA negative 6 months after the end of treatment)
An extended version of this table can be found in the supplementary material (Supplementary table 2).
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rhosis or liver stiffness of 13 kPa or more. Varices were
found in 4/9 (44%) of patients.
HCV genotype distribution (St. Gallen)
Genotype distribution among those with detectable HCV
RNA and thus still in need of treatment was as follows:
50% (33/66) with genotype 1, 24% (16/66) with genotype
3 and 26% (17/66) with genotype 4.
In contrast, genotype distribution among those who had
ever received HCV treatment was 43% (9/21) with geno-
type 1, 48% (10/21) with genotype 3 and 5% (1/21) with
genotype 4.
Delay of HCV diagnosis and treatment (St. Gallen)
The median delay from the estimated date of infection
(start of i.v.-drug use) to HCV diagnosis was 10 years
(range: –5 to 37 years, n = 136), and the median delay from
the diagnosis to the start of HCV treatment was another 7.5
years (range: 0–13 years, n = 20), resulting in a total me-
dian delay of 17 years (range: 5–33 years, n = 19) from
the estimated date of infection (start of i.v.-drug use) to the
therapy start (fig. 1).
Potential barriers to treatment (St. Gallen)
A substantial proportion of the 78 HCV RNA-positive pa-
tients had an alcohol consumption >40 g/d (26%), suffered
from depression (32%), had already attempted to commit
suicide (17%), and/or had a history of epilepsy (21%). In
contrast, thyroid disease was rather rare with 1%. Only
40% (31/78) had none of these five potential barriers to
treatment.
Figure 1
Delay of HCV diagnosis and treatment.
Comparison between patients ever treated and never
treated for HCV (St. Gallen)
HCV treatment uptake rates were highest in genotype 3 pa-
tients and lowest in genotype 4 patients (genotype 1: 24%
(9/37), genotype 3: 43% (10/23), genotype 4: 6% (1/18)).
HCV genotype 3 patients were significantly more likely
to receive treatment than patients with other genotypes
(OR 3.40 (1.15–10.25)). In contrast, HCV treatment up-
take was significantly lower in HIV-HCV-co-infected pa-
tients compared to HCV-mono-infected patients (OR 0.11
(0.005–0.67) (table 3).
There was a tendency towards a higher frequency of de-
pression and suicide attempts, and a lower prevalence of
alcohol-consumption >40 g/d in treated versus untreated
patients in St. Gallen (data collection in most cases after
the end of HCV treatment). However, differences were
not statistically significant (p values >0.2) (supplementary
table 3). Besides, a documentation bias favouring the docu-
mentation of depression and suicide attempts in treated pa-
tients cannot be excluded.
Patients receiving heroin substitution were over-represen-
ted among HCV-treated patients (OR for HCV treatment
uptake: 2.57 (0.95-6.96) for heroin versus methadone sub-
stitution, p = 0.06) (table 3 and supplementary table 3).
HIV-co-infection (St. Gallen and Bern)
Almost 80% (29/37) of HIV-positive patients in St. Gallen
were on antiretroviral treatment, translating to a proportion
of >70% (27/37) with completely suppressed viremia (i.e.
HIV RNA <50 cop/ml). About 80% (23/29) had an
abacavir and about 20% (5/29) underwent a tenofovir-
based HIV-therapy (in combination with lamivudine (3TC)
or emtricitabine (FTC)). For the majority (>90%; 27/29),
the regimen was protease inhibitor-based (given potential
interactions between non-nucleoside reverse transcriptase
inhibitors and methadone). Almost half of the patients
(46% (17/37)) had a CD4-nadir <200/ul. However, the
most recent CD4-count was ≥200/ul in about 90% (23/37)
of patients, ≥350/ul in 62% (23/37) and ≥500/ul in 41%
(15/37).
In KODA Bern, the proportion of HIV-positive patients on
antiretroviral treatment was 65% (17/26). Three of the nine
untreated individuals would have qualified for therapy ac-
cording to current guidelines.
Hepatitis A and B (St. Gallen and Bern)
Hepatitis A and B screening and vaccination in the case of
negative titers is a well-accepted standard of care in HCV
infected patients [2].
Table 3: Logistic regression derived odds ratios for treatment uptake.
St. Gallen
OR (95% CI)
SCCS
OR (95% CI)
SHCS
OR (95% CI)
Heroin vs. methadone substitution 2.57 (0.95–6.96) – –
Drug substitution program vs. never IDU – 0.32 (0.27–0.39) 0.47 (0.35–0.63)
HCV genotype 3 vs. other HCV genotype 3.40 (1.15–10.25) 1.69 (1.44–1.99) 2.29 (1.80–2.92)
HCV genotype 1 vs. HCV genotype 3 0.42 (0.14–1.27) 0.58 (0.49–0.69) 0.50 (0.39–0.64)
HCV genotype 4 vs. HCV genotype 3 0.08 (0.009–0.68) 0.41 (0.31–0.54) 0.27 (0.19–0.40)
HIV-HCV-co-infection vs. HCV-mono-infection 0.11 (0.005–0.67) 0.33 (0.25–0.44) –
Statistically significant results are highlighted with red colour.
OR = odds ratio, 95% CI = 95% confidence interval, SCCS = Swiss Hepatitis C Cohort Study, SHCS = Swiss HIV Cohort Study, IDU = intravenous drug use, HCV =
Hepatitis C virus, HIV = Human immunodeficiency virus
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In St. Gallen, hepatitis A/B-serology was lacking in about
10%. In those with available serology, three-quarters were
immune against hepatitis A (anti-HAV positive: 134/175)
and B (anti-HBc positive or anti-HBs >100 positive: 129/
171). A total of 50% of all patients were anti-HBc positive
(94/186; i.e. someday naturally infected), and only 1% (1/
160) were HBsAg positive (i.e. chronically infected; HBV-
DNA not determined). As a general observation, the hep-
atitis A/B vaccination status was often insufficiently docu-
mented.
In KODA Bern, hepatitis A/B-serology was also available
in about 90%. Of those, 81% (147/182) were anti-HAV
positive and 85% (158/186) were anti-HBs and/or anti-
HBc positive. The proportion with anti-HBc-positivity, and
thus the presumed previous infection, was 73% (135/186).
A positive HBs-Ag was found in 4% (7/186).
HCV treatment uptake and outcome in comparison
with SCCS and SHCS data
With 23% (HIV-: 29%, HIV+: 4%; St. Gallen) and 8%
(Bern), HCV treatment uptake in the absence of spontan-
eous clearance was lower in the investigated drug substitu-
tion programs than in the SCCS (57%; HIV-: 60%, HIV+:
33%) and the SHCS (28%, all HIV+) in general. It was also
lower than in drug substitution program participants within
the SCCS (38%; HIV-: 42%, HIV+: 22%) and SHCS (24%,
all HIV+), and particularly lower than in non-IDUs within
the SCCS (65%; HIV-: 68%, HIV+: 58%) and SHCS (36%,
all HIV+) (table 2 and supplementary table 2).
The odds ratios for HCV treatment uptake and SVR in
comparison with St. Gallen are given in table 4.
For patients with genotype known, SVR-rates were about
50% (genotype 1: 36-37%, genotype 3: 65-66%) both in
the SCCS and SHCS, which is comparable with those in
the drug substitution programs of St. Gallen (table 2).
Within the SCCS, SVR-rates were not significantly higher
in HIV-negative compared to HIV-positive patients (54%
versus 44%, p = 0.20; OR 1.49 (0.80–2.80)). Within the
SHCS, not significantly higher SVR-rates were achieved
in non-IDUs than in patients in drug substitution programs
(54% versus 46%, p = 0.35; OR 1.39 (0.70–2.80)).
However, the opposite was observed in the SCCS (49% in
non-IDUs versus 64% in opioid substitution program parti-
cipants, p = 0.002; OR 0.55 (0.37–0.81)) (table 2).
Comparison between patients treated at least once and
patients never treated for HCV (SCCS and SHCS)
Similar to the observations in the three drug substitution
programs of St. Gallen, SCCS and SHCS patients with
HCV genotype 1 and 4 were less likely to receive HCV
treatment compared to genotype 3 patients (p <0.01). Like-
wise, the likelihood of HCV treatment uptake was signi-
ficantly lower for HIV-HCV-co-infected patients than for
HCV-mono-infected patients in the SCCS (OR 0.33
(0.25–0.44), p <0.01). Drug substitution program parti-
cipants were significantly less likely to get HCV treatment
than patients without IDU as a risk factor both in the SCCS
and SHCS (p <0.01) (table 3).
Discussion
HCV-screening
Considering the multiple difficulties in the medical man-
agement of drug addicts and prior study results, the dia-
gnostic work-up of HCV was better than expected.
In Zurich, the most highly populated canton in Switzerland,
the HepCOP1-Study demonstrated, in 2008, that 50% of all
patients treated with methadone substitution were insuffi-
ciently screened for HCV (in 29% there was no HCV an-
tibody test, in 22% of the anti-HCV-positives there was no
HCV RNA and in 53% of the HCV RNA-positives no gen-
otype was available) [3, 18]. In the three drug substitution
programs in St. Gallen, we observed incomplete HCV as-
sessment in only 14% (27/196) (in 1% a HCV antibody
test was missing, in 9% HCV RNA was lacking and in
15% genotype was lacking). However, in about 50% of
the HCV-negative screened patients, the last test was older
than one year. Difficulties to obtain blood by venous punc-
ture in former IDUs might complicate retesting, which can
be overcome by using capillary diagnostic tools [19]. In
June 2010, the first HCV-rapid test (OraQuick® HCV Rap-
id Antibody test) was FDA-approved (http://www.fda.gov/
NewsEvents/Newsroom/PressAnnouncements/
ucm217318.htm).
HCV treatment uptake
Insufficient HCV treatment uptake (particularly in HIV-
co-infected patients) is still a major problem, although the
cost-effectiveness of HCV treatment has been shown in
several studies [20, 21]. Achieving SVR means long-term
remission of disease, with liver-related mortality compar-
able to the general population [22]. Drug substitution pro-
Table 4: Comparison of HCV treatment uptake and success between St. Gallen, Bern, SCCS and SHCS.
OR for HCV treatment uptake (95% CI) OR for SVR (95% CI)
St. Gallen 1 1
Bern 0.28 (0.12–0.68) 1.88 (0.34–10.46)
SCCS 4.38 (2.67–7.16) 1.26 (0.48–3.30)
SHCS 1.32 (0.83–1.47) 1.15 (0.43–3.07)
Drug substitution program in the SCCS 2.00 (1.20–3.32) 1.99 (0.72–5.50)
Drug substitution program in the SHCS 1.02 (0.60–1.73) 0.94 (0.32–2.79)
Non-IDU in the SCCS 6.06 (3.68–9.98) 1.09 (0.41–2.86)
Non-IDU in the SHCS 1.85 (1.10–3.13) 1.32 (0.46–3.78)
Statistically significant results are highlighted with red colour.
OR = odds ratio, 95% CI = 95% confidence interval, SVR = sustained virological response (HCV RNA negative 6 months after the end of treatment), SCCS = Swiss
Hepatitis C Cohort Study, SHCS = Swiss HIV Cohort Study, IDU = intravenous drug use, HIV = Human immunodeficiency virus
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grams have improved survival of IDUs [3]. However, the
extended life expectancy increases the relevance of HCV-
induced liver morbidity and mortality [23]. The costs of
HCV treatment with pegylated interferon and ribavirin (ap-
proximately 20’000 CHF for genotype 1 and 15’000 CHF
for genotype 2/3 [24]) must be weighed against the costs
for liver transplantation (120’000 CHF) [25], post-trans-
plantation care as well as management of decompensated
liver cirrhosis and HCC [23].
According to historical SCCS data from 2006/2007, 44%
(485/1092) of non-IDUs, but only 8.7% (77/882) of pa-
tients in opioid substitution programs were treated for their
chronic hepatitis C [2, 7]. The current data show an im-
provement to 65% for non-IDUs and 38% for heroin/meth-
adone recipients (table 2). Thus, the treatment gap tends
to decrease but has not disappeared, although adherence,
side effects and treatment outcome do not differ (no matter
whether IDU is entirely stopped or still ongoing) [6]. This
trend might be a result of the new international consensus
guidelines of 2002, not advising against HCV treatment in
IDUs and heroin/methadone recipients anymore [26–28].
Treatment uptake-rates in HIV-co-infected patients were
consistently lower both in the SCCS (overall: 33%, in drug
substitution program: 22%) and the SHCS (overall: 28%,
in drug substitution program: 24%) compared to 60% in
HCV-mono-infected SCCS-participants (table 2).
Comparing treated with untreated patients (supplementary
table 3), non-IDUs and HCV-genotype 3-infected patients
(possibly faster fibrosis progression than other genotypes
[29]) were more likely to receive therapy, and methadone/
heroine recipients, HCV-genotype 4-infected and HIV-co-
infected patients were less likely to receive therapy (table
3). Lower treatment response rates in HCV-genotype 4 as
well as HIV-co-infected patients (generally 10–15% lower
than in HCV-mono-infected) [30], and a longer duration
of therapy might be an obstacle. Among treated patients,
methadone recipients were under-represented and heroin
recipients were over-represented, suggesting that the heroin
setting with a low yearly fluctuation and twice daily con-
tacts allowing DOT is advantageous for HCV treatment.
The low treatment rate in KODA Bern may be explained
by the lack of somatic physicians in a program mainly
focussed on psychiatric care. Several potential barriers to
treatment (mainly alcohol abuse, depression, former sui-
cide attempts, epilepsy) must be managed prior to and dur-
ing HCV therapy, demanding a multidisciplinary approach
including psychiatrists, neurologists and hepatologists and/
or infectious diseases specialists. Absolute abstention from
alcohol and IDU is not mandatory during HCV treatment,
as long as adherence is not jeopardised [6, 31].
Delay of HCV diagnosis and treatment
In contrast to HIV, HCV is a potentially curable disease
with the best responses to treatment in its acute phase
(80–90% SVR irrespective of genotype), i.e. if treated
within 12 weeks in patients whose acute HCV-infection
does not spontaneously resolve by week 8 [32, 33]. Once
liver fibrosis has developed, HCV treatment becomes less
effective [34] and in the case of decompensated liver cir-
rhosis, liver transplantation remains the last option.
However, even the new AASLD practice guidelines from
2009 continue to recommend HCV treatment still mainly,
when liver fibrosis is already established [35].
Due to its often asymptomatic course, hepatitis C is usually
not diagnosed in its acute phase. Taking into account that
new IDUs are at high risk of acquiring HCV infection
shortly after initiating injecting [36, 37], the day of the first
intravenous drug use might serve as a proxy for the date of
HCV-infection in IDUs. Accordingly, in the drug substitu-
tion programs of St. Gallen, the median delay between the
“estimated date of infection” (IDU start) and the first dia-
gnosis of HCV was 10 years and the median delay between
diagnosis and treatment initiation was another 7.5 years.
Thus, the median lag time from infection to treatment was
approximately 17 years, a time frame in which cirrhosis
can already develop (up to 20% over a 20–25-year peri-
od [38]). Advanced age results in a reduced treatment re-
sponse [35] and the period of infectiousness is extended
(fig. 1).
In IDUs, faster liver disease progression must be postulated
because of multiple additional hepatotoxic factors such as
alcohol [39], cannabis [40, 41], HBV- [42] and HIV-co-in-
fection [9, 10], as well as co-medication. Accordingly, a
general indication for HCV treatment in IDUs irrespective
of the fibrosis grade might be worth discussion.
One argument in favour of postponing treatment would be
to wait for the availability of new, more effective drugs
for difficult-to-treat genotypes. In 2012, the protease-inhib-
itors telaprevir and boceprevir will come onto the market
for HCV-genotype 1, increasing treatment response rates to
>70%, in some cases after only 24–28 weeks (comparable
to genotype 2/3) [43]. In combination with ribavirin and
pegylated interferon, twice daily telaprevir seems not to be
inferior to three times a day [44], permitting DOT. This is
of special relevance for the patients in the three drug sub-
stitution programs in St. Gallen, because among those still
in need of treatment (currently HCV RNA positive) 50%
(33/66) have genotype 1. Certainly, additional side effects
(more anaemia and rashes) must be managed, at least with
the first generation protease inhibitors.
However, the best medicine is useless, if it is not applied.
Thus, not only an improvement of drugs, but also a further
increase of treatment uptake is necessary in order to pre-
vent more liver-related deaths by HCV treatment [22]. In
a US-survey, the primary reason for lack of treatment was
lack of diagnosis (about 50% of respondents), another 24%
were recommended by their doctor not to be treated and
only 12% finally received treatment [22]. A total of 72% of
primary care physicians would not refer a patient with nor-
mal liver enzymes for treatment [45], despite evidence that
such patients can develop progressive disease [46].
HCV treatment outcomes
Irrespective of HIV- and IDU-status, SVR rates were quite
similar in the investigated drug substitution programs in St.
Gallen and Bern as well as in the SCCS and SHCS, which
were about 50% overall (table 2 and supplementary table
2).
In this context, a Swiss study was only recently published
reporting equal SVR rates for HCV-mono- and HIV-HCV-
co-infected patients with favourable HCV genotypes 2 and
3 after only 6 months of Peginterferon alpha 2a plus rib-
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avirin [47]. As already mentioned above, several studies
have shown comparable HCV treatment response rates for
IDUs and non-IDUs [4–6, 48]. Within the SCCS, SVR-
rates were even significantly higher in methadone/heroin-
recipients compared to non-IDUs (64% versus 49%,
p <0.01). This might be partly explained by the fact that:
1) current or former IDUs have only been treated for a
short time and thus were not exposed to less effective treat-
ment regimens of the past, 2) HCV RNA 6 months after
the end of treatment is more likely to be available in com-
pliant patients who are also more likely to have treatment
success and 3) substituted patients often experience a more
intensive care during their HCV-therapy than non-IDUs.
However, a selection bias due to stricter patient selection
cannot be excluded.
Limitations
Some of the patients in the three largest drug substitution
programs in St. Gallen were also participants in the SCCS
and SHCS.
Conclusions/Future Strategies
In order to increase the number of liver-related deaths pre-
vented by HCV treatment, not only better drugs which
are needed, but also treatment uptake must also be in-
creased (Volk, 2009), particularly in participants of drug
substitution programs and HIV-co-infected patients who
are currently significantly undertreated despite a compar-
able treatment response.
HCV-negative patients at risk should be screened in regular
intervals [2] to diagnose HCV earlier and treatment should
be offered as soon as possible after diagnosis to prevent
a delay of treatment. The latter accounts for an increasing
risk of developing liver cirrhosis and HCC, and a reducing
chance of treatment response over time (already estab-
lished fibrosis, age >40 years) as well as for an uninterrup-
ted transmission chain (fig. 1), which constitutes a socio-
economic problem.
A total of 50% of the patients still in need of treatment
(i.e. currently HCV RNA positive) have HCV genotype 1,
for which the new protease-inhibitors telaprevir and bo-
ceprevir will be available in 2012, increasing SVR rates
to >70%, for some patients after only 24 weeks, which
is comparable to genotype 2/3. Twice daily dosing of tel-
aprevir and ribavirin in combination with peginterfon-in-
jections once a week permits DOT, particularly in heroin
substitution programs. The treatment outcome in HCV gen-
otype 4 might improve with the availability of the new
polymerase-inhibitors effective irrespective of genotype.
Due to the numerous co-morbidities and social problems
linked to drug addiction, HCV treatment in drug substitu-
tion program participants demands an interdisciplinary ap-
proach involving social workers, drug addiction specialists,
psychiatrists, neurologists and hepatologists/infectious dis-
eases specialists. Insidiously, chronic hepatitis C is usually
clinically silent until advanced stages of liver disease have
occurred. Thus, insight into the illness and treatment readi-
ness cannot be taken for granted, but must be inspired.
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Supplementary Material
Supplementary table 1: Characteristics of the three drug substitution programs in St. Gallen (extended version).
MSH1 MSH2 H22
Founded 1995 1993 1990
Substituted drug Heroin i.v. 2x/d Methadone p.o. 1x/d Methadone p.o. 1x/d
Capacity (patients) Max. 75 Max. 100 35
Yearly fluctuation (patients) about 8 (10%) 50–60 (about 50%) about 5 (14%)
Open (days/week) 7 6 5
Medical care 2x 50% somatic physician on-site +
infection case discussions at least every
6 weeks
2x 50% somatic physician on-site +
infection case discussions at least every
6 weeks
Outpatient Clinic of the Department of
Infectious Diseases
Number of patients included in the cross
sectional study
71 90 35
Gender (female) 23% (16/71) 23% (21/90) 31% (11/35)
Median age (years) (range) 42 (26–63) 39 (20–63) 42 (29–61)
Median time in program since last admission
(years) (range)
5.0 (0–14) 2.0 (0–16) 3.7 (0–19)
Frequency of attendance
– daily
– several times a day
100% (71/71)
93% (66/71)
77% (69/90)
1% (1/90)
87% (30/35)
11% (4/35)
Opioid substitution
– heroin
– methadone
– buprenorphine
94% (67/71)
6% (4/71)
0% (0/71)
0% (0/90)
97% (87/90)
3% (3/90)
0% (0/35)
100% (35/35)
0% (0/33)
Never IDU 5% (3/67) 22% (20/90) 0% (0/35)
HIV- and HCV-negative 17% (12/71) 38% (33/87) 0% (0/35)
HCV-infection (anti-HCV+) 82% (58/71) 61% (54/88) 97% (34/35)
HCV RNA+, if anti-HCV+ and HCV RNA
available
48% (27/56) 63% (27/43) 71% (24/34)
HIV-infection 18% (13/71) 0% (0/88) 69% (24/35)
HIV-HCV-co-infection 17% (12/71) 0% (0/87) 66% (23/35)
SCCS-participation, if HCV+ 50% (29/58) 33% (18/54) 88% (30/34)
SHCS-participation, if HIV+ 100% (13/13) NA* 100% (24/24)
MSH1 = heroin substitution program of the addiction aid trust St. Gallen, MSH2 = methadone substitution program of the addiction aid trust St. Gallen, H22 = methadone
substitution program of the Outpatient Clinic of the Department of Infectious Diseases of the Cantonal Hospital St. Gallen, i.v. = intravenous, p.o. = per os, max. = maximal,
IDU = intravenous drug use, HIV = Human immunodeficiency virus, HCV = Hepatitis C virus, SCCS = Swiss Hepatitis C Cohort Study, SHCS = Swiss HIV Cohort Study,
NA = not applicable, * no HIV+ patients
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Supplementary table 2: Patient characteristics, HCV treatment uptake and success rates (extended version).
SCCS SHCS St. Gallen Bern
Number of patients 3602 16285 196 202
Median age (years) (range) 48 (19–91) 48 (18–101) 41 (20–63) 39 (21–71)
Gender (female) 37% (1335/3602) 29% (4659/16285) 25% (48/196) 28% (57/202)
Drug substitution program 24% (872/3600) 9% (796/8517) 100% 100%
No IDU 43% (1534/3595) 71% (11326/15960) 12% (23/190) 0%
HCV-infected 100% 29% (3319/11527) 75% (146/194) 80% (161/200)
HCV RNA+, if anti-HCV+ and HCV RNA
available
68% (2425/3575) 67% (1446/2153) 59% (78/133) 65% (97/150)
HIV-infected 10% (285/2974) 100% 19% (37/194) 13% (26/195)
HIV-HCV-co-infected 10% (285/2974) 29% (3319/11527) 18% (35/193) 13% (26/195)
Liver biopsy, if no spontaneous clearance 66% (2234/3374) 40% (696/1752) 35% (32/91) No data
HCV treatment uptake rates SCCS SHCS St. Gallen Bern
– all chronically HCV infected 57% (1915/3374) 28% (497/1752) 23% (21/91) 8% (8/102)
– HIV-HCV-co-infected (HIV+) 33% (82/246) 28% (497/1752) 4% (1/23) 10% (2/21)
– HCV-mono-infected (HIV-) 60% (1517/2519) – 29% (20/68) 7% (6/81)
– all in drug substitution program 38% (282/753) 24% (128/545) 23% (21/91) 8% (8/102)
– drug substitution and HIV+ 22% (27/123) 24% (128/545) 4% (1/23) 10% (2/21)
– drug substitution and HIV- 42% (234/564) – 29% (20/68) 7% (6/81)
– all non-IDUs 65% (963/1493) 36% (159/445) – –
– non-IDU and HIV+ 58% (18/31) 36% (159/445) – –
– non-IDU and HIV- 68% (737/1084) – – –
Proportion with SVR, if treated SCCS SHCS St. Gallen Bern
– all (with known genotype) 53% (564/1066) 50% (116/230) 47% (8/17) 63% (5/8)
– all with genotype 1 37% (176/474) 36% (32/89) 38% (3/8) 0% (0/1)
– all with genotype 3 66% (264/399) 65% (69/106) 67% (4/6) 71% (5/7)
– all HIV+ (with known genotype) 44% (19/43) 50% (116/230) 0% (0/1) 100% (2/2)
– HIV+ with genotype 1 38% (8/21) 36% (32/89) 0% (0/1) –
– HIV+ with genotype 3 50% (10/20) 65% (69/106) – 100% (2/2)
– all HIV- (with known genotype) 54% (464/856) – 50% (8/16) 50% (3/6)
– HIV- with genotype 1 38% (140/369) – 43% (3/7) 0% (0/1)
– HIV- with genotype 3 68% (226/334) – 67% (4/6) 60% (3/5)
– all in drug substitution program (with
known genotype)
64% (85/133) 46% (26/57) 47% (8/17) 63% (5/8)
– drug substitution and genotype 1 57% (24/42) 45% (14/31) 38% (3/8) 0% (0/1)
– drug substitution and genotype 3 67% (53/79) 46% (10/22) 67% (4/6) 71% (5/7)
– all non-IDUs (with known genotype) 49% (274/557) 54% (41/76) – –
– non-IDU with genotype 1 33% (98/294) 44% (12/27) – –
– non-IDU with genotype 3 63% (74/118) 74% (23/31) – –
SCCS = Swiss Hepatitis C Cohort Study, SHCS = Swiss HIV Cohort Study, IDU = intravenous drug use, HCV = Hepatitis C virus, HIV = Human immunodeficiency virus,
SVR = sustained virological response (HCV RNA negative 6 months after the end of treatment)
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Supplementary table 3: Characteristics of patients treated versus not treated for hepatitis C (St. Gallen, SCCS, SHCS).
Treated
(St. Gallen)
Not treated
(St. Gallen)
p
values*
Treated
(SCCS)
Not treated
(SCCS)
p
values*
Treated
(SHCS)
Not treated
(SHCS)
p
values*
Median age at first diagnosis
(years) (range)
33 (18–50) 31 (19–54) 38 (10–78) 35 (8–81) 35 (18–58) 34 (16–68)
Median age at treatment start
(years) (range)
38 (21–57) – 43 (16–80) – 42 (23–61) –
Median time since first diagnosis
at treatment start (years) (range)
7.5 (0–13) – 3 (0–38) – 7 (0–20) –
Methadone substitution 48% (10/
21)
70% (49/
70)
p = 0.06 – – – –
Heroin substitution 52% (11/
21)
30% (21/
70)
p = 0.06 – – – –
Drug substitution program – – 14% (263/
1828)
32% (460/1435) p <0.001 28% (128/453) 45% (418/930) p <0.001
Never IDU – – 51% (927/
1824)
37% (524/1433) p <0.001 26% (129/488) 16% (198/1272) p <0.001
Genotype 1 45% (9/20) 48% (28/
58)
p = 0.80 46% (677/
1460)
55% (769/1404) p <0.001 45% (179/397) 52% (574/1109) p = 0.02
Genotype 3 50% (10/
20)
22% (13/
58)
p = 0.02 36% (518/
1460)
25% (344/1404) p <0.001 42% (167/397) 24% (267/1109) p <0.001
Genotype 4 5% (1/20) 29% (17/
58)
p = 0.03 8% (114/1460) 13% (184/1404) p <0.001 10% (39/397) 20% (228/1109) p <0.001
HIV-co-infection 5% (1/21) 31% (22/
70)
p = 0.01 5% (79/1534) 14% (161/1149) p <0.001 – –
Depression 43% (9/21) 30% (21/
70)
p = 0.27
Suicide attempt 29% (6/21) 16% (11/
70)
p = 0.31
Alcohol-consumption >40 g/d 14% (3/21) 27% (19/
70)
p = 0.22
Epilepsy 24% (5/21) 19% (13/
70)
p = 0.80
Thyroid disease 10% (2/21) 0% (0/70) p = 0.10
* p values were calculated with Chi-square or Fisher’s exact test, when sample sizes was small. Statistically significant results are highlighted with red colour.
SCCS = Swiss Hepatitis C Cohort Study, SHCS = Swiss HIV Cohort Study, IDU = intravenous drug use, HIV = Human immunodeficiency virus
Original article Swiss Med Wkly. 2011;141:w13193
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 12 of 12
